TY - JOUR AU - Kanetsky P. AU - Dwyer T AU - Orlow I. AU - Luo L. AU - Kricker A. AU - Armstrong B. AU - Anton-Culver H. AU - Gruber S. AU - Marrett L. AU - Gallagher R. AU - Zanetti R. AU - Rosso S. AU - Begg C. AU - Berwick M. AU - Thomas N. AU - Reiner A. AU - Paine S. AU - Roy P. AU - Busam K. AB -

Factors known to affect melanoma survival include age at presentation, sex and tumor characteristics. Polymorphisms also appear to modulate survival following diagnosis. Result from other studies suggest that vitamin D receptor (VDR) polymorphisms (SNPs) impact survival in patients with glioma, renal cell carcinoma, lung, breast, prostate and other cancers; however, a comprehensive study of VDR polymorphisms and melanoma-specific survival is lacking. We aimed to investigate whether VDR genetic variation influences survival in patients with cutaneous melanoma. The analysis involved 3566 incident single and multiple primary melanoma cases enrolled in the international population-based Genes, Environment, and Melanoma Study. Melanoma-specific survival outcomes were calculated for each of 38 VDR SNPs using a competing risk analysis after adjustment for covariates. There were 254 (7.1%) deaths due to melanoma during the median 7.6 years follow-up period. VDR SNPs rs7299460, rs3782905, rs2239182, rs12370156, rs2238140, rs7305032, rs1544410 (BsmI) and rs731236 (TaqI) each had a statistically significant (trend P values < 0.05) association with melanoma-specific survival in multivariate analysis. One functional SNP (rs2239182) remained significant after adjustment for multiple testing using the Monte Carlo method. None of the SNPs associated with survival were significantly associated with Breslow thickness, ulceration or mitosis. These results suggest that the VDR gene may influence survival from melanoma, although the mechanism by which VDR exerts its effect does not seem driven by tumor aggressiveness. Further investigations are needed to confirm our results and to understand the relationship between VDR and survival in the combined context of tumor and host characteristics.

AD - Department of Dermatology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Department of Internal Medicine, Epidemiology and Cancer Prevention, University of New Mexico, Albuquerque, NM 87131, USA.
Sydney School of Public Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
Prevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario M5G 2L7, Canada.
Piedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin 10126, Italy.
USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Department of Epidemiology, School of Medicine, University of California at Irvine, Irvine, CA 92617, USA.
Cancer Control Research, British Columbia Cancer Research Centre, Vancouver, British Columbia V5Z 1L3, Canada.
The George Institute for Global Health, Oxford Martin School, University of Oxford, Oxford OX1 3BD, UK and.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. AN - 26521212 BT - Carcinogenesis C2 - PMC4715233 DA - 93625559517 DP - NLM ET - 2015/11/02 LA - eng LB - UK
FY16 M1 - 1 N1 - Orlow, Irene
Reiner, Anne S
Thomas, Nancy E
Roy, Pampa
Kanetsky, Peter A
Luo, Li
Paine, Susan
Armstrong, Bruce K
Kricker, Anne
Marrett, Loraine D
Rosso, Stefano
Zanetti, Roberto
Gruber, Stephen B
Anton-Culver, Hoda
Gallagher, Richard P
Dwyer, Terence
Busam, Klaus
Begg, Colin B
Berwick, Marianne
GEM Study Group
P30 CA008748/CA/NCI NIH HHS/United States
R01 CA112243/CA/NCI NIH HHS/United States
R01 CA112524/CA/NCI NIH HHS/United States
U01 CA083180/CA/NCI NIH HHS/United States
UL1 TR001449/TR/NCATS NIH HHS/United States
England
Carcinogenesis. 2016 Jan;37(1):30-8. doi: 10.1093/carcin/bgv157. Epub 2015 Oct 31. N2 -

Factors known to affect melanoma survival include age at presentation, sex and tumor characteristics. Polymorphisms also appear to modulate survival following diagnosis. Result from other studies suggest that vitamin D receptor (VDR) polymorphisms (SNPs) impact survival in patients with glioma, renal cell carcinoma, lung, breast, prostate and other cancers; however, a comprehensive study of VDR polymorphisms and melanoma-specific survival is lacking. We aimed to investigate whether VDR genetic variation influences survival in patients with cutaneous melanoma. The analysis involved 3566 incident single and multiple primary melanoma cases enrolled in the international population-based Genes, Environment, and Melanoma Study. Melanoma-specific survival outcomes were calculated for each of 38 VDR SNPs using a competing risk analysis after adjustment for covariates. There were 254 (7.1%) deaths due to melanoma during the median 7.6 years follow-up period. VDR SNPs rs7299460, rs3782905, rs2239182, rs12370156, rs2238140, rs7305032, rs1544410 (BsmI) and rs731236 (TaqI) each had a statistically significant (trend P values < 0.05) association with melanoma-specific survival in multivariate analysis. One functional SNP (rs2239182) remained significant after adjustment for multiple testing using the Monte Carlo method. None of the SNPs associated with survival were significantly associated with Breslow thickness, ulceration or mitosis. These results suggest that the VDR gene may influence survival from melanoma, although the mechanism by which VDR exerts its effect does not seem driven by tumor aggressiveness. Further investigations are needed to confirm our results and to understand the relationship between VDR and survival in the combined context of tumor and host characteristics.

PY - 2016 SN - 1460-2180 (Electronic)
0143-3334 (Linking) SP - 30 EP - 8 T2 - Carcinogenesis TI - Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study VL - 37 Y2 - FY16 ER -